StockTipsArenaBeta

BUY Cipla Ltd. — Dhvani Patel

BUYCipla Ltd.
Cipla share price target & all analyst calls

byDhvani PatelHorizon: NA (inferred 1–3 months)30 Jun 2026via CNBC Awaaz.

Entry₹1,495Stated
Target₹1,540
Total upside +3.01% (call closed)
Stop loss₹1,450-3.01% risk
Exit—No position was opened
ExpiredNAauction close
Follow Dhvani Patel for new callsGet alertsWatch CIPLA for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Sept 2026
16 supporting19 neutral17 opposing
Supports the BUY call (16)

8 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·29 Sept · yesterday

2 other SEBI-registered advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·21 Sept · 1w ago

Wockhardt Share Price Today: 2.19% rise and sector view

NewsGoogle News·17 Sept · 2w ago

(opens in new tab)

Explained: Why Morgan Stanley has the second-lowest price target on the Street for this drugmaker

NewsCnbc-Tv18·4 Sept · 4w ago

(opens in new tab)

Cipla announces exclusive US partnership with Qilu Pharma for keytruda biosimilar

NewsCnbc-Tv18·3 Sept · 4w ago

(opens in new tab)
Neutral / worth noting (19)

ICICI Lombard, United Breweries And Cipla: Three Stocks That Bucked The Trend As Stock Market Crashed

NewsNdtv-Profit·24 Sept · 5d ago

(opens in new tab)

Anthem Biosciences Share Price Today: valuation and peers

NewsGoogle News·18 Sept · 2w ago

(opens in new tab)

SYMBIOTEC Share Price News: price rise and valuation view

NewsGoogle News·18 Sept · 2w ago

(opens in new tab)

Cipla Ltd is intimating shareholders and creditors about a notice regarding a Scheme of Amalgamation (by Absorption) of Inzpera Healthsciences Limited with Cipla Limited. The notice provides an opport

BSE · Company Update·3 Sept · 4w ago

(opens in new tab)
Weighs against the BUY call (17)

US Drug Tariff: 15 Pharma Stocks Likely to Be Impacted by Trump’s New Tariff Plan

NewsGoogle News·16 Sept · 2w ago

(opens in new tab)

Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field

NewsHbl·4 Sept · 4w ago

(opens in new tab)

3 advisors have active long-term SELL calls on this stock

Advisor consensus · adjacent horizon·24 Jul · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Cipla

All analyst calls on Cipla

More from Dhvani Patel

Every call and its outcome